Last edition
News about "immune cell migration "
Asahi Kasei Pharma Signs Exclusive License Deal for Anti-CX3CR1 Antibody
The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell migration to inflammatory sites.
Immune Cell Migration | 12/12/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members